Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-05-03
2005-05-03
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S172000, C436S139000, C424S001450
Reexamination Certificate
active
06887861
ABSTRACT:
A method for improving intracellular administration of a therapeutic agent is provided comprising: contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the cell transport the compound into the cell where the cell metabolizes at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.
REFERENCES:
patent: 5389623 (1995-02-01), Bodor
patent: 5502037 (1996-03-01), Kondratyev
patent: 5505931 (1996-04-01), Pribish
patent: 5554498 (1996-09-01), Filler et al.
patent: 5563250 (1996-10-01), Hylarides et al.
patent: 5614652 (1997-03-01), Filler et al.
patent: 5767288 (1998-06-01), Rock et al.
patent: 5833988 (1998-11-01), Friden
patent: 5948384 (1999-09-01), Filler
patent: 5977307 (1999-11-01), Friden et al.
patent: WO 9310234 (1993-05-01), None
patent: WO 9507092 (1995-03-01), None
patent: WO 9532738 (1997-03-01), None
patent: WO 9723608 (1997-03-01), None
patent: WO 9721732 (1997-06-01), None
patent: WO 9726275 (1997-07-01), None
patent: WO9737966 (1997-10-01), None
patent: WO 9841220 (1998-09-01), None
patent: WO 9921552 (1999-05-01), None
patent: WO0037103 (2000-06-01), None
patent: WO0191798 (2001-12-01), None
Agarwal, et al., “Effects of dexamethasone (DEX) on growth factor and neurotrophin mRNA expression by cultured human trabecular meshwork cells”, IOVS (Mar. 15, 1999) vol. 40, No. 4, pp. S667 (Ann Mtg. of the Assoc for Research in Vision and Ophthalmology Fort Lauderdale, Florida, USA May 9-14, 1999).
Gonzalez, et al., “Glucocorticoid regulation of motoneuronal parameters in rats with spinal cord injury”, Cellular and Molecular Neurobiology, (Oct. 1999) vol. 19, No. 5, pp. 597-611.
Nemoto, et al., “A possible mechanism of TPA-mediated downregulation of neurotrophin-3 gene expression in rat cultured vascular smooth muscle cells”, Molecular Brain Research, (May 7, 1999) vol. 68, No. 1-2, pp. 186-189.
Smith, et al., “Regulation of NGFI-A (Egr-1) gene expression by the POU domain transcription factor Brn-3a”, Brain Research, Molecular Brain Research, (Dec. 10, 1999) 74 (1-2) 117-25.
Shi, et al., “Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor”, Journal of Neuroscience, (Nov. 15, 1998) vol. 18, No. 22, pp. 9326-9334.
Yang, et al., “Dexamethasone inhibits ischemia-induced transient reduction of neurotrophin-3 mRNA in rat hippocampal neurons”, Neuroreport, (Oct. 26, 1998) vol. 9, No. 15, pp. 3477-3480.
Verity, et al., “Regulation of glial cell line-derived neurotrophic factor release from rat C6 blioblastoma cells”, Journal of Neurochemistry, (Feb. 1998) vol. 70, No. 2, pp. 531-539.
Brandoli, et al., “Dexamethasome decreases P75NTR expression in injured spinal cord”, Society for Neuroscience Abstracts, (1998) vol. 24, No. 1-2, pp. 290 (28thAnn Mtg. of the Society for Neuroscience, Part 1).
Prodanov, et al., “Pharmacology of apoptosis in the central nervous system”, Farmatsiya, (Sofia) (1998), 45(2), 31-38.
Fink Jr., et al., “Effect of glucocorticoid on NGF-stimulated TRKA signaling in PC12 cells”, Society for Neuroscience Abstracts, (1997) vol. 23, No. 1-2, pp. 1702(27thAnn Mtg. of the Society for Neuroscience, New Orleans, Louisiana, USA Oct. 25-30, 1997).
Seidl, et al., “Expression of nerve growth factor and neurotrophin receptors in testicular cells suggest novel roles for neurotrophin outside the nervous system”, Reproduction Fertility and Development, (1996) vol. 8, No. 7, pp. 1075-1087.
Barbany, “Modulation of neurotrophins and their receptors by adrenal steroids”, CNS Neurotransmitters and Neuromodulators: Neuroactive Steroids (1996), 113-125.
Scully, et al, “Neuotrophin expression modulated by glucocorticoids and oestrogen in immortalized hippocampal neurons”, Molecular Brain Research, (1995) vol. 31, No. 1-2, pp. 158-164.
Higaki, et al., “NeurotropinRinhibits lipopolysaccharide-induced nitric oxide production in cultured human endothelial cells”, Cell structure and function, (1994) vol. 19, No. 6, pp. 555 (47theAnn Mtg. of the Japan Society for Cell Biology, Nagasaki, Japan, Sep. 28-30, 1994).
Kononen, et al., “Neurotropins and their receptors in the rat pituitary gland: regulation of BDNF and trk B mRNA levels by adrenal hormones”, Molecular Brain Research, (1994) vol. 27, No. 2, pp. 347-354.
Lindholm, et al., “Glucocorticoids and neurotrophin gene regulation in the nervous system”, Annals of the New York Academy of Sciences, (Nov. 30, 1994) 746, 195-202.
Jelsma, et al., “Different forms of the neurotrophin receptor trk B mRNA predominate in rat retina and optic nerve”, Journal of Neurobiology, (1993) vol. 24, No. 9, pp. 1207-1214.
Barbany, et al., “Adrenalectomy attenuates kainic acid-elicited increases of messenger RNAs for neurotrophins and their receptors in the rat brain”, Neuroscience, (1993) vol. 54, No. 4, pp. 909-922.
Cosi, et al., “Glucocorticoids depress activity-dependent expression of BDNF mRHA in hippocampal neurons”, Neuroreport, (1993) vol. 4, No. 5, pp. 527-530.
Scully, et al., “Modulation of neurotrophin expression by glucocorticoids in immortalized hippocampal neurons”, Society for Neuroscience Abstract, (1993) vol. 19, No. 1-3, pp. 256 (23rdAnn Mtg. of the Society for Neuroscience, Washington D.C., USA, Nov. 7-12, 1993).
Scully, et al., “glucocorticoid modulation of neurotrophin expression in immortalized mouse hippocampal neurons”, Neuroscience Letters, (1993) vol. 155, No. 1, pp. 11-14.
Barbany, et al., “Regulation of Neurotrophin mRNA Expression in the rat brain by glucocorticoids”, Eur J. Neurosci, (1992) 4 (5) 396-403.
(6472179 or 6410510 or 6077829 or 5827823 or 5648334 or 5599506 or 5622862 or 5512661 or 5438121 or 5349056 or 6472178 or 5846935 or 5229500) .pn. 555 6837, Aug. 7, 2003.
Binkley et al., “RNA Ligands to Human Nerve Growth Factor,”Nucleic Aciods Researchvol. 23, No. 16: pp. 3198-3205 (1995).
Fiume et al., “Galactosylated poly(L-lysine) as a Hepatotropic Carrier of 9-β-D-arabinofuranosyldenine 5′-monophosphate,”FEBS3810 vol. 203 No. 2: pp. 203-206 (Jul. 1986).
Fiume et al., “Drug Targeting in Antiviral Chemotherapy: A Chemically Stable Conjugate of 9-β-D-Arabinofuranosyl-Adenine 5′-Monophosphate with Lactosaminated Albumin Accomplishes a Selective Delivery of the Drug to Liver Cells,”Biochemical Pharmacologyvol. 35 No. 6: pp. 967-972 (1986).
Haschke et al., “Preparation and Retrograde Axonal Transport of an Antiviral Drug/Horseradish Peroxidase Conjugate,”Journal of Neurochemistryvol. 35 No. 6: pp. 1431-1435 (Dec. 1980).
Kramer et al., “Monoclonal Antibody to human Trk-A: Diagnostic and Therapeutic Potential in Neuroblastoma,”European Journal of Cancervol. 33 No. 12: pp. 2090-2091 (Oct. 1997).
Li et al., “α-Endorphin Omission Analogs: Dissociation of Immunoreactivity from Other Biological Activities,”Proc. Natl. Acad. Sci. USA 77(6): 3211-3214 (1980) (cited on PTO-892 as “Choh et al”).
Maliartchouk et al., “Optimal Nerve Growth Factor Trophic Signals Mediated by Synergy of TrkA and p75 Receptor-Specific Ligands,”Journal of Neurosciencevol. 17 No. 16: pp. 6031-6037 (1997).
Pardridge et al., “Tranport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood-B
Hill Gordon Craig
Kahl Stephen B.
McKee Constance A.
Webb Robert R.
Asilomar Pharmaceuticals, Inc.
Bozicevic Field & Francis LLP
Francis Carol J.
Landsman Robert
LandOfFree
Compounds for intracellular delivery of therapeutic moieties... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for intracellular delivery of therapeutic moieties..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for intracellular delivery of therapeutic moieties... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3450659